Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03473756 |
|---|---|
| Brief Title: | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) |
| First Submitted : | March 16, 2018 |
| First Submitted that Met QC Criteria : | March 21, 2018 |
| First Posted : | March 22, 2018 |
| Last Update Submitted that Met QC Criteria : | May 10, 2022 |
| Last Update Posted : | May 16, 2022 |